Roivant Sciences has launched Lokavant, a technology company to offer real-time and anticipatory clinical trial monitoring to study sponsors and contract research organisations (CROs).

Lokavant aims to ensure that clinical trials do not fail due to operational error.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With the integration and analysing of the disparate data sources within clinical trials, Lokavant offers real-time visualisations and risk alerts to study sponsors and CROs so that they can take data-driven decisions.

Lokavant offers trial data to power a machine learning model that can predict trial risk, offers risk mitigation strategies, and forecasts the impact of mitigation strategy implementation.

The anticipatory monitoring capability is based on a collection of data drawn from more than 1,000 clinical trials and Lokavant expects this capability to improve with each deployment.

Rohit Nambisan, who was earlier the head of digital product at Roivant Sciences, has been appointed president of Lokavant.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lokavant has signed its first multi-year enterprise license agreement with contract research organisation Parexel.

Parexel will make use of the Lokavant platform to boost the operational execution of clinical trials through improved real-time risk-based monitoring.

Parexel CEO Jamie Macdonald said: “Lokavant and Parexel share a focus on innovation in clinical development.

“We look forward to deploying Lokavant’s platform to access real-time data-driven insights for our sponsors, to ultimately improve clinical trial execution and accelerate the delivery of important new therapies to patients.”